VYGR - Voyager Therapeutics Inc Stock Price, Fair Value and News

9.26USD+0.07 (+0.76%)Market Closed

Market Summary

USD9.26+0.07

Market Closed

0.76%

VYGR Stock Price

View Fullscreen

VYGR RSI Chart

VYGR Valuation

Market Cap

503.7M

Price/Earnings (Trailing)

-165.47

Price/Sales (Trailing)

3.16

EV/EBITDA

164.29

Price/Free Cashflow

61.18

VYGR Price/Sales (Trailing)

VYGR Profitability

EBT Margin

-1.55%

Return on Equity

-0.89%

Return on Assets

-0.65%

Free Cashflow Yield

1.63%

VYGR Fundamentals

VYGR Revenue

Revenue (TTM)

150.5M

Rev. Growth (Yr)

-87.03%

Rev. Growth (Qtr)

61.76%

VYGR Earnings

Earnings (TTM)

-3.0M

Earnings Growth (Yr)

-109.13%

Earnings Growth (Qtr)

-120.09%

Breaking Down VYGR Revenue

Last 7 days

10.6%

Last 30 days

18.7%

Last 90 days

21.5%

Trailing 12 Months

6.8%

How does VYGR drawdown profile look like?

VYGR Financial Health

Current Ratio

5.64

VYGR Investor Care

Shares Dilution (1Y)

24.94%

Diluted EPS (TTM)

-0.14

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	0	0	0	0
2023	68.3M	95.7M	123.1M	150.5M
2022	38.3M	39.2M	40.0M	40.9M
2021	159.6M	132.2M	15.9M	37.4M
2020	117.3M	99.9M	197.3M	171.1M
2019	11.9M	55.4M	73.7M	104.4M
2018	9.6M	11.0M	12.0M	7.6M
2017	10.9M	8.3M	6.2M	10.1M
2016	19.6M	18.4M	16.8M	14.2M
2015	0	0	0	17.3M

Get all data in R, Python etc through our Historical Stock Data APIs

About Voyager Therapeutics Inc

Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of Alzheimer's disease. It also develops VY-FXN01 to treat Friedreich's ataxia; superoxide dismutase 1 gene silencing program for the treatment of amyotrophic lateral sclerosis; and GBA1 gene replacement program to treat Parkinson's disease. In addition, the company develops research program for the treatment of Huntington's disease. It has collaboration and license agreements with Neurocrine Biosciences, Inc.; Pfizer Inc.; and Novartis Pharma, A.G. for the research, development, and commercialization of adeno-associated virus gene therapy products. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.

CEO	Dr. Alfred W. Sandrock Jr., M.D., Ph.D.
WEBSITE	voyagertherapeutics.com
INDUSTRY	Biotechnology
EMPLOYEES	125

Voyager Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for Voyager Therapeutics Inc? What does VYGR stand for in stocks?

VYGR is the stock ticker symbol of Voyager Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Voyager Therapeutics Inc (VYGR)?

As of Fri Jul 26 2024, market cap of Voyager Therapeutics Inc is 503.68 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of VYGR stock?

You can check VYGR's fair value in chart for subscribers.

Is Voyager Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether VYGR is over valued or under valued. Whether Voyager Therapeutics Inc is cheap or expensive depends on the assumptions which impact Voyager Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for VYGR.

What is Voyager Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Jul 26 2024, VYGR's PE ratio (Price to Earnings) is -165.47 and Price to Sales (PS) ratio is 3.16. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. VYGR PE ratio will change depending on the future growth rate expectations of investors.